Submitted a clinical trial authorization (CTA) application to the medicines and healthcare products regulatory agency (MHRA) in UK to initiate a Phase 1 study of ALN-HSD for the treatment of nonalcoholic steatohepatitis (NASH)
Study initiation expected in late 2020, upon obtaining MHRA approval
Alnylam to initiate trial for its first RNAi in NASH in 2020
Share this
CI Scientists Remarks:
In 2018, Alnylam and Regeneron entered into a fifty-fifty collaboration to research, co-develop and commercialize ALN-HSD is an investigational, subcutaneously administered RNAi therapeutic, targeting HSD17B13 gene for the treatment of nonalcoholic steatohepatitis
Regeneron identified for the first time a variant in the HSD17B13 gene that is associated with reduced risk of chronic liver diseases and Alnylam leveraged its RNAi therapeutics platform to identify the compound (ALN-HSD) directed to this gene
ALN-HSD utilizes Alnylam’s Enhanced Stabilization Chemistry Plus (ESC+) GalNAc-conjugate technology, which enables subcutaneous dosing with increased selectivity and a wide therapeutic index